Shares of Vera Therapeutics Inc. (VERA) are currently up nearly 63% at $30.88, following positive results from its ORIGIN 3 trial.
ORIGIN 3 is a phase III trial of its investigational drug Atacicept for the treatment of immunoglobulin A nephropathy (IgAN) in adults.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com